Home » Infectious diseases: 1,500 hospitalizations in Udine in six months, monoclonal for 40 patients

Infectious diseases: 1,500 hospitalizations in Udine in six months, monoclonal for 40 patients

by admin

The director of the Tascini clinic: these numbers were recorded in five years

UDINE. The Udine infectious disease clinic had never faced such intense activity as the one managed in the second phase of the pandemic. “In six months we have hospitalized 1,500 patients, a number equal to that recorded in the previous five years”.

The infectious disease specialist, Carlo Tascini, director of the structure of the central Friuli health authority, says this to give credit to the activity carried out in conditions that are certainly not easy, even to all his collaborators and to the staff who gravitate around the clinic. In the department with over 60 beds, everything is ready to start the administration of new monoclonal drugs.

Despite the pressure they are subjected to, infectious disease doctors and nurses also manage outpatient care for patients treated with monoclonal antibodies.

In Udine, the monoclonal drug “Bamlanivimab” has already been administered to 40 patients with Covid-19 and previous diseases, in the very first phase of the infection.

“Monoclonal antibodies with the Spike protein must be administered to non-hospitalized patients who do not undergo oxygen therapy” explains the director, recalling that in the literature, the same drugs are reported for patients infected with Sars-CoV2 within five days of contagion, while the Italian Medicines Agency (Aifa) authorized the administration of monoclonals up to 10 days from the infection.

Among the requisites there is also the age. In some cases, depending on the pathologies they already suffer from, the monoclonal is only prescribed to patients over 55 years old. The administration of monoclonal antibodies has been authorized only for compassionate use therefore only for those who run the most risks. “On an experimental basis – Tascini has already had the opportunity to explain – the drug has shown a reduction in viral load and symptoms. It has not yet been validated to reduce mortality ».

See also  Secret documents show that the EU's asylum reform is in danger of failing

On Tuesday, in the infectious disease clinic of the Central Friuli University Health Authority (Asufc), a sort of second phase will open with regard to the administration of monoclonal antibodies, the new generation drugs, also tested by the former president of the United States, Donald Trump. «From Tuesday – continues the director – we will start administering a mixture of two monoclonals“ Casirivimab ”and“ Imdevimab ”». All monoclonals are taken in a single dose in the Udine clinic’s outpatient clinic by patients who do not need hospitalization.

In fact, once the infusion and the observation period are exhausted, the sick return to their homes. The administration of monoclonal antibodies is part of the home care provided for by the protocol written by the three infectious disease specialists of the region: Tascini, Massimo Crapis and Roberto Luzzati, directors, respectively, of the clinic in Pordenone and of the department of Trieste.

In recent days, the three directors have illustrated the document to the presidents of the Medical Orders and to the general practitioners with whom they are carrying out an effective collaboration. It is often the general practitioner who reports patients with previous pathologies affected by Covid-19 for a few days to infectious disease specialists. The reservation and then the administration of the drug in the clinic follows.

The appointment can be booked by contacting the Infectious Diseases clinic in Udine directly on 0432/552590. The administration of monoclonal antibodies is also carried out in the Infectious Diseases clinic of the Western Friuli Health Authority directed by Crapis.

See also  Mama Vila, mother of Diomedes Díaz, celebrated her 86th birthday

.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy